Sabrin Tahri

Sabrin Tahri is an active Hematology Researcher at Erasmus University Medical Center's Erasmus School of Medicine in Rotterdam, specializing in multiple myeloma pathophysiology and tumor microenvironment dynamics. Her work integrates immunology, molecular biology, and clinical oncology to investigate cellular mechanisms driving disease progression and treatment response.

Her primary research focuses on the immunological landscape of multiple myeloma, particularly examining NK cell functionality, stromal-tumor interactions, and inflammatory signaling pathways. Key investigations include the role of IL-1β in neutrophil-stromal crosstalk, BAFF-mediated protumor microenvironments, and daratumumab's immunomodulatory effects. She employs advanced techniques like single-cell transcriptomics to dissect cellular heterogeneity within bone marrow niches.

Analysis of her publication trajectory reveals consistent exploration of microenvironmental drivers in multiple myeloma, with increasing emphasis on translational immunology since 2021. Her work bridges basic science (stromal cell biology, cytokine networks) with clinical applications (MRD prediction, daratumumab response biomarkers), demonstrating strong collaborative networks across European hematology research groups.

Tahri actively participates in large-scale collaborative research through extensive co-authorship networks, contributing to high-impact studies in Nature Immunology and Blood. Her recent work demonstrates involvement in clinical trial correlative studies and multi-institutional translational projects focused on microenvironment-targeted therapies.

Her laboratory work centers on characterizing cellular components of the myeloma bone marrow niche, with particular expertise in stromal cell biology, neutrophil-mediated inflammation, and NK cell cytotoxicity. Current investigations focus on identifying microenvironmental predictors of treatment response using integrated omics approaches.